Breaking News Instant updates and real-time market news.

NTLA

Intellia Therapeutics

$15.20 /

+0.72 (+4.97%)

08:02
01/09/20
01/09
08:02
01/09/20
08:02

Intellia Therapeutics expects preclinical data for HAE program in 1Q20

Intellia announced that the Company is committed to developing a CRISPR/Cas9-based therapy for hereditary angioedema as its third development program. HAE is a rare genetic disorder characterized by recurring and unpredictable severe swelling attacks in various parts of the body, and is significantly debilitating or even fatal in certain cases. The disease is caused by increased levels of bradykinin, a protein which leads to swelling. Most patients with HAE have a C1 esterase inhibitor protein deficiency, which normally prevents the unregulated release and buildup of bradykinin. Using its modular LNP-based CRISPR/Cas9 delivery system, Intellia aims to knock out the kallikrein B1 gene, which is part of a biological pathway that results in release of bradykinin. Knocking out this gene should reduce the undesired bradykinin activity in HAE patients. The Company plans to present preclinical data at an upcoming scientific meeting in the first quarter of 2020. In addition, Intellia is evaluating several potential guide RNAs and expects to nominate a development candidate in the first half of 2020. Intellia's KLKB1 HAE program is subject to an option by Regeneron to enter into a Co/Co agreement, in which Intellia would remain the lead party.

NTLA Intellia Therapeutics
$15.20 /

+0.72 (+4.97%)

12/16/19 Roth Capital
Roth says Intellia profit, but also costs, could change under Regeneron pact
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
11/01/19 Raymond James
Intellia Therapeutics upgraded to Outperform at Raymond James
11/01/19 Raymond James
Intellia upgraded to Outperform from Market Perform at Raymond James

TODAY'S FREE FLY STORIES

Hot Stocks
Cellect Biotechnology receives new patent allowance in China » 08:02
04/02/20
04/02
08:02
04/02/20
08:02
APOP

Cellect Biotechnology

$1.39 /

-0.08 (-5.44%)

Cellect Biotechnology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
LondonMetric upgraded to Buy from Hold at Jefferies » 08:01
04/02/20
04/02
08:01
04/02/20
08:01
LNSPF

LondonMetric

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Upgrade
Land Securities Group upgraded to Buy from Underperform at Jefferies » 08:00
04/02/20
04/02
08:00
04/02/20
08:00
LSGOF

Land Securities Group

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Nordic American Tankers says start of Q2 'much stronger' than Q1 » 08:00
04/02/20
04/02
08:00
04/02/20
08:00
NAT

Nordic American Tankers

$4.39 /

-0.13 (-2.88%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Gilead call buyer realizes 31% same-day gains » 08:00
04/02/20
04/02
08:00
04/02/20
08:00
GILD

Gilead

$72.55 /

-2.21 (-2.96%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Great Portland Estates upgraded to Buy from Underperform at Jefferies » 07:59
04/02/20
04/02
07:59
04/02/20
07:59
GPEAF

Great Portland Estates

/

+

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Jiayin Group downgraded to Neutral from Buy at Roth Capital » 07:59
04/02/20
04/02
07:59
04/02/20
07:59
JFIN

Jiayin Group

$2.33 /

-0.22 (-8.63%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Rent-A-Center participates in a conference call with Stifel » 07:59
04/02/20
04/02
07:59
04/02/20
07:59
RCII

Rent-A-Center

$12.91 /

-1.22 (-8.63%)

Home Furnishings &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
EnerSys price target lowered to $75 from $80 at Oppenheimer » 07:58
04/02/20
04/02
07:58
04/02/20
07:58
ENS

EnerSys

$44.07 /

-5.28 (-10.70%)

Oppenheimer analyst Noah…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Biomerica signs agreements with Mount Sinai Medical School for serological test » 07:58
04/02/20
04/02
07:58
04/02/20
07:58
BMRA

Biomerica Inc

$7.02 /

-0.12 (-1.68%)

Biomerica announced it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Upgrade
Gecina upgraded to Buy from Hold at Jefferies » 07:58
04/02/20
04/02
07:58
04/02/20
07:58
GECFF

Gecina

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Empiric Student Property upgraded to Buy from Hold at Jefferies » 07:57
04/02/20
04/02
07:57
04/02/20
07:57
EPCFF

Empiric Student Property

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
CarMax up 7% to $56.20 after Q4 results beat estimates  07:57
04/02/20
04/02
07:57
04/02/20
07:57
KMX

CarMax

$52.20 /

-1.53 (-2.85%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Meridian Bioscience says many clinical trial partners have suspended operations » 07:56
04/02/20
04/02
07:56
04/02/20
07:56
VIVO

Meridian Bioscience

$7.82 /

-0.575 (-6.85%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Derwent London upgraded to Buy from Underperform at Jefferies » 07:56
04/02/20
04/02
07:56
04/02/20
07:56
DWVYF

Derwent London

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Parker-Hannifin price target lowered to $150 from $185 at Baird » 07:56
04/02/20
04/02
07:56
04/02/20
07:56
PH

Parker-Hannifin

$116.05 /

-13.53 (-10.44%)

Baird analyst Mig Dobre…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Meridian Bioscience says has not experienced any material supply chain issues » 07:56
04/02/20
04/02
07:56
04/02/20
07:56
VIVO

Meridian Bioscience

$7.82 /

-0.575 (-6.85%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Inspire Medical price target lowered to $42 from $50 at Oppenheimer » 07:55
04/02/20
04/02
07:55
04/02/20
07:55
INSP

Inspire Medical

$51.65 /

-8.43 (-14.03%)

Oppenheimer analyst Suraj…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Okta price target raised to $130 from $120 at Oppenheimer » 07:55
04/02/20
04/02
07:55
04/02/20
07:55
OKTA

Okta

$119.49 /

-2.64 (-2.16%)

Oppenheimer analyst Shaul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Capital & Counties upgraded to Hold from Underperform at Jefferies » 07:55
04/02/20
04/02
07:55
04/02/20
07:55
CCPPF

Capital & Counties

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Meridian Bioscience expects Exalenz merger to be complete before June 30 » 07:55
04/02/20
04/02
07:55
04/02/20
07:55
VIVO

Meridian Bioscience

$7.82 /

-0.575 (-6.85%)

Exalenz Bioscience…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Oil Action: WTI crude » 07:55
04/02/20
04/02
07:55
04/02/20
07:55

Oil Action: WTI crude…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
JPMorgan LatAm commodities analysts to hold an analyst/industry conference call » 07:55
04/02/20
04/02
07:55
04/02/20
07:55

LatAm Pulp & Paper…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
Unite Group upgraded to Buy from Hold at Jefferies » 07:54
04/02/20
04/02
07:54
04/02/20
07:54
UTGPF

Unite Group

$0.00 /

+ (+0.00%)

Jefferies analyst Mike…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Earnings
Meridian Bioscience not updating FY20 guidance at this time  07:54
04/02/20
04/02
07:54
04/02/20
07:54
VIVO

Meridian Bioscience

$7.82 /

-0.575 (-6.85%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.